New drug trial aims to tame MS in young patients
Disease control
Not yet recruiting
This study is testing a drug called ublituximab in children and teenagers (ages 10-18) with relapsing multiple sclerosis (RMS). The main goals are to see how the drug works in the body and to find out if it is at least as good as an existing treatment (fingolimod) at reducing the…
Phase: PHASE2, PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC